首页> 美国卫生研究院文献>World Journal of Gastroenterology >CCR5Δ32 mutation does not influence the susceptibility to HCV infection severity of liver disease and response to therapy in patients with chronic hepatitis C
【2h】

CCR5Δ32 mutation does not influence the susceptibility to HCV infection severity of liver disease and response to therapy in patients with chronic hepatitis C

机译:CCR5Δ32突变不会影响慢性丙型肝炎患者对HCV感染的敏感性肝病的严重性以及对治疗的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To study whether CCR5Δ32 mutation was associated with viral infection and severity of liver disease.METHODS: Two hundred and fifty two histologically proven, chronic HCV patients (mean age: 41 ± 14 years; M/F: 164/88) were genotyped. PCR based genotyping of 32 bp deletion at the CCR5 locus was done. Four-hundred and eight matched healthy controls were studied to assess susceptibility to HCV infection. To assess correlation of immune gene polymorphism with severity of HCV related liver disease, patients with chronic HCV infection were divided into those with a fibrosis score of ≤ 2 (mild) or > 2 (severe) and histological activity index (HAI) of ≤ 5 or > 5. For correlation between CCR5Δ32 mutations and response to therapy, 129 patients who completed therapy were evaluated.RESULTS: The majority (89.4%) of the patients were infected with genotype 3. The frequency of homozygous CCR5Δ32 mutants was comparable to HCV patients as compared to the healthy controls (0.7% vs 0%, P = 0.1). Further more, the frequency of CCR5∆32 mutation was comparable in patients with mild or severe liver disease. (P = NS). There was also no association observed with response to therapy and CCR5Δ32 mutation.CONCLUSION: CCR5Δ32 mutation does not have a role in disease susceptibility, severity or response to therapy in patients with chronic hepatitis C infection.
机译:目的:研究CCR5Δ32突变是否与病毒感染和肝病严重程度有关。方法:对252例经组织学证实的慢性HCV患者(平均年龄:41±14岁;男/女:164/88)进行基因分型。 。在CCR5基因座进行了32 bp缺失的基于PCR的基因分型。研究了四百八十个匹配的健康对照者,以评估其对HCV感染的敏感性。为了评估免疫基因多态性与HCV相关肝病严重程度的相关性,将慢性HCV感染患者分为纤维化评分≤2(轻度)或> 2(重度)且组织活性指数(HAI)≤5或> 5.为评估CCR5Δ32突变与治疗反应之间的相关性,对完成治疗的129名患者进行了评估。结果:大多数患者(89.4%)被感染了基因型3。纯合CCR5Δ32突变体的频率与HCV患者相当与健康对照组相比(0.7%vs 0%,P = 0.1)。此外,在轻度或重度肝病患者中,CCR5Δ32突变的频率相当。 (P = NS)。结论:CCR5Δ32突变与慢性丙型肝炎患者的疾病易感性,严重性或对治疗的反应无关,但与治疗反应和CCR5Δ32突变无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号